AI Article Synopsis
- A 35-year-old male had multiple car accidents, inability to keep his room tidy, and developed speech and walking difficulties beginning at age 34.
- His initial examination revealed mild cognitive impairment with a Mini-Mental State Examination (MMSE) score of 23, but he was still able to walk and talk independently.
- After three months, his condition worsened, leading to severe loss of speech, coordination issues, and mobility problems, ultimately diagnosed as Sez6l2 antibody-associated autoimmune cerebellar ataxia, which improved slightly with immunotherapy.
Article Abstract
A 35-year-old male patient had been repeatedly involved in car accidents since the age of 34 years, had difficulty in tidying his room, and developed speech and gait disorders. At the first examination, he had a hypophonia and poor gait, but he could talk and walk by himself. His Mini-Mental State Examination (MMSE) score was 23 and mild cognitive impairment was observed. Three months later, neurological findings showed subacute progression to loss of speech, and poor right dominant diadochokinesia and finger tapping, poor finger-nose test and heel-knee test, and loss of ability to stand and walk. Cerebellar atrophy was observed on head MRI, and the patient was positive for Seizure-related 6 homolog like 2 (Sez6l2) antibody, leading to a diagnosis of Sez6l2 antibody-associated autoimmune cerebellar ataxia. Immunotherapy halted the progression of symptoms, and the patient showed slight improvement. Sez6l2 antibody measurement and immunotherapy were considered necessary for subacute progressive cerebellar ataxia of unknown cause.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5692/clinicalneurol.cn-001869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
J Clin Endocrinol Metab
September 2024
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Article Synopsis
- Seizure-related 6 homolog (SEZ6) is linked to neuroendocrine differentiation and has been found to be highly expressed in medullary thyroid carcinoma (MTC), as well as small cell lung carcinoma (SCLC).
- A novel antibody drug, ABBV-011, targeting SEZ6 is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, suggesting potential therapeutic applications.
- SEZ6 shows high immunoexpression in a majority of MTC cases, making it a promising biomarker, even though it does not correlate with patient outcomes or certain mutations, highlighting its potential for targeted therapy.
Article Synopsis
Article Synopsis
- The study examines the transcriptional and epigenomic changes in the human cerebellum related to Alzheimer's disease (AD) and AD-related dementias, evaluating 103,861 nuclei from AD cases and controls through advanced genome analysis techniques.
- Researchers identified thousands of significant connections between gene expression and chromatin accessibility, focusing on key transcription factors RORA and ELF1 in specific cerebellar cell types, which correlate with disease-specific changes.
- The analysis also highlighted two potentially crucial genes, SEZ6L2 and KANSL1, that may play a role in the pathology of AD, providing new insights into the genetic and epigenetic factors influencing neurological disorders.
Objective: This article reviews the clinical and antibody spectrum of autoimmune cerebellar ataxia and other autoimmune movement disorders. It highlights characteristic phenotypes and red flags to the diagnosis and how these rare, but treatable, disorders are integrated into a differential diagnosis.
Latest Developments: An increasing number of neuronal antibodies have been identified in patients with cerebellar ataxia, for example, against Kelch-like protein 11 (KLHL11), seizure-related 6 homolog-like 2, septin-3 and septin-5, or tripartite motif containing protein 9 (TRIM9), TRIM46, and TRIM67.
Novel human neurodevelopmental and neurodegenerative disease associated with IRF2BPL gene variants-mechanisms and therapeutic avenues.
Front Neurosci
June 2024
Quantitative Stem Cell Biology, Berlin Institute for Medical Systems Biology (BIMSB) Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.
Recently a broad range of phenotypic abnormalities related to the neurodevelopmental and neurodegenerative disorder NEDAMSS (Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures) have been associated with rare single-nucleotide polymorphisms (SNPs) or insertion and deletion variants (Indel) in the intron-less gene IRF2BPL. Up to now, 34 patients have been identified through whole exome sequencing carrying different heterozygous pathogenic variants spanning the intron-less gene from the first polyglutamine tract at the N-terminus to the C3HC4 RING domain of the C-terminus of the protein. As a result, the phenotypic spectrum of the patients is highly heterogeneous and ranges from abnormal neurocognitive development to severe neurodegenerative courses with developmental and seizure-related encephalopathies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!